Healthcare / Pharmaceutical RetailersTokyo
$505.00
-1.00 (-0.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.0B · quality 32.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.8B
P/E
N/A
•EV/EBITDA
9.0x
↓ROE
-5.3%
↓Gross Margin
14.1%
↓Debt/Equity
2.08
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.2%
FCF CAGR
+35.1%
FCF margin
1.0%
FCF / Net income
-1.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $63.51B · net income $-367.0M · FCF $609.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $63.51B | $63.51B | $54.47B | $52.03B | $51.61B |
| Net Income | $-367.0M | $-367.0M | $-351.0M | $333.0M | $447.0M |
| EBITDA | $1.68B | $1.68B | $1.38B | $2.33B | $2.69B |
| EPS | -32.48 | -32.48 | -33.41 | 26.89 | 36.29 |
| Gross Margin | 14.1% | 14.1% | 15.5% | 15.6% | 15.7% |
| Operating Margin | 0.5% | 0.5% | 1.7% | 2.8% | 2.9% |
| Net Margin | -0.6% | -0.6% | -0.6% | 0.6% | 0.9% |
| Balance Sheet | |||||
| Debt/Equity | 2.08 | 2.08 | 1.73 | 1.33 | 1.50 |
| Current Ratio | 0.93 | 0.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $609.0M | $609.0M | $2.10B | $1.98B | $247.0M |
| Returns | |||||
| ROE | -5.3% | -5.3% | -4.8% | 4.8% | 6.8% |
| Valuation | |||||
| P/E | — | — | — | 22.72 | 19.59 |
| EV/EBITDA | 8.98 | 8.98 | 8.89 | 4.36 | 4.66 |
| P/B | 0.83 | 0.83 | 0.91 | 0.83 | 1.00 |
| Growth & Yield | |||||
| Revenue Growth | 16.6% | 16.6% | 4.7% | 0.8% | — |
| EPS Growth | 2.8% | 2.8% | -224.2% | -25.9% | — |
| Dividend Yield | 2.8% | 2.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-33.41 → -32.48
Residual
+3.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.